Search

Your search keyword '"Rashal T"' showing total 17 results

Search Constraints

Start Over You searched for: Author "Rashal T" Remove constraint Author: "Rashal T" Search Limiters Full Text Remove constraint Search Limiters: Full Text
17 results on '"Rashal T"'

Search Results

1. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies

2. Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

Catalog

Books, media, physical & digital resources

3. Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)

4. Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) in Patients with Head & Neck Squamos Cell Carcinoma (Hn-Scc)

5. Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Exportin 1 (Xpo1) Antagonist Selinexor (Kpt-330) in Patients (Pts) with Platinum Resistant/Refractory Ovarian Cancer (Ovca)

6. Selinexor (Kpt-330), an Oral, Selective Inhibitor of Nuclear Export (Sine) Shows Anti-Prostate Cancer (Prca) Activity Preclinically & Disease Control in Patients (Pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (Crpc)

7. 886P - Circulating tumor cell number predicts time to progression (TTP) in patients with heavily pretreated gynecological cancers treated with selinexor (SEL)

8. 854O - Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers

10. 888P - Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Exportin 1 (Xpo1) Antagonist Selinexor (Kpt-330) in Patients (Pts) with Platinum Resistant/Refractory Ovarian Cancer (Ovca)

11. 758O - Selinexor (Kpt-330), an Oral, Selective Inhibitor of Nuclear Export (Sine) Shows Anti-Prostate Cancer (Prca) Activity Preclinically & Disease Control in Patients (Pts) with Chemotherapy Refractory, Castrate-Resistant Prostate Cancer (Crpc)

12. Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro .

13. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia.

14. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

15. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.

16. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.

17. Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.